A plain language review of the TETON-1 and TETON-2 studies: inhaled treprostinil (Tyvaso) in idiopathic pulmonary fibrosis

Plain Language SummaryWhat is this plain language review about?This review explains two clinical studies called TETON-1 and TETON-2. These studies looked at a medicine called inhaled treprostinil in people with idiopathic pulmonary fibrosis (IPF). IPF is a disease that causes scarring in the lungs and makes it hard to breathe.What were TETON-1 and TETON-2?The TETON-1 and TETON-2 studies were clinical trials that lasted 52 weeks (about 1 year). Researchers compared inhaled treprostinil with a placebo, which is a treatment that looks similar to the medication being studied but does not contain the active medication.What were the results and what do they mean?Treprostinil slowed the decline of lung function in people with IPF. They also had fewer clinical worsening events (, such as a large decrease in lung function, a hospital stay, or death) and reported better quality of life.Clinical trial numbers: NCT04708782, NCT05255991